Молекулярнохгенетические прогностические маркеры рака мочевого пузыря (обзор литературы)

Автор: Измайлов А.А.

Журнал: Сибирский журнал клинической и экспериментальной медицины @cardiotomsk

Статья в выпуске: 4-1 т.26, 2011 года.

Бесплатный доступ

Рак мочевого пузыря (РМП) остается актуальной проблемой онкоурологии. Несмотря на то, что факторы риска РМП многократно изучены и описаны в литературе, ежегодно выявляются дополнительные генетические поломки, предраспологающие к развитию заболевания. В патогенез РМП вовлечено множество клеточных процессов. Менее агрессивные, неинвазивные, медленно прогрессирующие формы РМП характеризуются активацией системы Ras-MAPK. Более агрессивные опухоли с низкой раковоспецифической выживаемостью характеризуются изменениями в генах ретинобластомы и p53. Предпринимаются попытки разработать прогностические тесты, предсказывающие поведение опухоли, возможно, повлияющие на выбор тактики лечения. В перспективе в лечении пациентов РМП будут использоваться молекулярно-генетические маркеры, позволяющие достоверно предсказать поведение опухоли у пациента и выбрать индивидуальную тактику лечения.

Еще

Рак мочевого пузыря, молекулярно-генетические маркеры, прогноз

Короткий адрес: https://sciup.org/14919601

IDR: 14919601

Список литературы Молекулярнохгенетические прогностические маркеры рака мочевого пузыря (обзор литературы)

Aoki S., Yamada Y., Nakamura K. et al. Thymidine phosphorylase expression as a prognostic marker for predicting recurrence in primary superficial bladder cancer//Oncol. Rep. -2006. -Vol. 16. -P. 279-284.
Bartsch G., Mitra A.P., Cote R.J. Expression profiling for bladder cancer: strategies to uncover prognostic factors//Expert Review of Anticancer Therapy. -2010. -Vol. 10 (12). -P. 1945-1954.
Birkhahn M., Williams A.J. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles//Eur. Urol. -2010. -Vol. 57 (1). -P. 12-20.
Birkhahn M., Mitra A.P., Cote R.J. Molecular markers for bladder cancer: the road to a multimarker approach Expert Rev//Anticancer Ther. -2007. -Vol. 7 (12). -P. 1717-1727.
Brown N.S., Jones A., Fujiyama C. et al. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors//Cancer Res. -2000. -Vol. 6. -P. 298-302.
Eissa S., Ali#Labib R., Swellam M. et al. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP#2) in urine//Eur. Urology. -2007. -Vol. 52 (5). -P. 1388-1397.
Ferlay J., Autier P., Boniol M. et al. Estimates of the cancer incidence and mortality in Europe in 2006//Ann. Oncol. -2007. -Vol. 18 (3). -P. 581-592.
Frum R., Ramamoorthy M., Mohanraj L. MDM2 controls the timely expression of cyclin A to regulate the cell cycle//Mol. Cancer. Res. -2009. -Vol. 7. -P. 1253-1267.
Gerhards S., Jung K., Koenig F. et al. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma//Urology. -2001. -Vol. 57. -P. 675-679.
Gonzalez-Campora R., Davalos-Casanova G., Beato-Moreno A. et al. BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma//Cancer Lett. -2007. -Vol. 250. -P. 292-299.
Grossman H.B., Lee C., Bromberg J. et al. Expression of the a6b4 integrin provides prognostic information in bladder cancer//Oncol. Rep. -2000. -Vol. 7. -P. 13-16.
Hanahan D., Weinberg R.A. The hallmarks of cancer//Cell. -2000. -Vol. 100. -P. 57-70.
Hehlgans S., Haase M., Cordes N. Signalling via integrins: implications for cell survival and anticancer strategies//Biochim. Biophys. Acta. -2007. -Vol. 1775 (1). -P. 163-180.
Hussain S.A., Ganesan R., Hiller L. et al. BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder//Oncol. Rep. -2003. -Vol. 10. -P. 571-576.
Jebar A.H., Hurst C.D., Tomlinson D.C. et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma//Oncogene. -2005. -Vol. 24. -P. 5218-5225.
Karam J.A., Lotan Y., Karakiewicz P.I. et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy//Lancet Oncol. -2007. -Vol. 8. -P.128-136.
Kramer C., Klasmeyer K., Bojar H. et al. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome//Cancer. -2007. -Vol. 109. -P. 2016-2024.
Kruger S., Weitsch G., Buttner H. et al. Overexpression of cerbB 2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome//Int. J. Oncol. -2002. -Vol. 21. -P. 981-987.
Manfredi J.J. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor//Genes Dev. -2010. -Vol. 24. -P. 1580-1589.
Mhawech-Fauceglia P., Fischer G., Beck A. et al. Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma: a retrospective TMA study of 246 patients with long#term follow#up//Eur. J. Surg. Oncol. -2006. -Vol. 32. -P. 439-444.
Mitra A.P., Almal A.A., George B. et al. The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer//BMC Cancer. -2006. -Vol. 6. -P. 159-160.
Mitra A.P., Cote R.J. Searching for novel therapeutics and targets: insights from clinical trials//Urol. Oncol. -2007. -Vol. 25. -P. 341-343.
Mitra A.P., Lin H., Cote R.J. et al. Biomarker profiling for cancer diagnosis, prognosis and therapeutic management//Nat. Med. J. India. -2005. -Vol. 18. -P. 304-312.
Mitra A.P., Lin H., Datar R.H. et al. Molecular biology of bladder cancer: prognostic and clinical implications//Clin. Genitourin. Cancer. -2006. -Vol. 5. -P. 67-77.
Moll U.M., Petrenko O. The MDM2#p53 Interaction//Mol. Cancer. Res. -2003. -Vol. 1. -P. 1001-1002.
Nadaoka J., Horikawa Y., Saito M. et al. Prognostic significance of HIF#1a polymorphisms in transitional cell carcinoma of the bladder//Int. J. Cancer. -2008. -Vol. 122. -P. 1297-1302.
Nonomura N., Nakai Y., Nakayama M. et al. The expression of thymidine phosphorylase is a prognostic predictor for the intravesical recurrence of superficial bladder cancer//Int. J. Clin. Oncol. -2006. -Vol. 11. -P. 297-302.
Palit V., Phillips R.M., Puri R. et al. Expression of HIF#1a and Glut-1 in human bladder cancer//Oncol. Rep. -2005. -Vol. 14. -P. 909-913.
Perabo F.G., Kamp S., Schmidt D. et al. Bladder cancer cells acquire competent mechanisms to escape Fasmediated apoptosis and immune surveillance in the course of malignant transformation//Br. J. Cancer. -2001. -Vol. 84. -P. 1330-1338.
Sanchez-Carbayo M., Socci N.D., Kirchoff T. et al. A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer//Clin. Cancer Res. -2007. -Vol. 13. -P. 3215-3220.
Simon R., Struckmann K., Schraml P. et al. Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer//Oncogene. -2002. -Vol. 21. -P. 2476-2483.
Szarvas T., Dorp F., Ergьn S. et al. Matrix metalloproteinases and their clinical relevance in urinary bladder cancer//Nat. Rev. Urol. -2011. -Vol. 8 (5). -P. 1-8.
Theodoropoulos V.E., Lazaris A., Sofras F. et al. Hypoxia-inducible factor 1a expression correlates with angiogenesis and unfavorable prognosis in bladder cancer//Eur. Urol. -2004. -Vol. 46. -P. 200-208.
Theodoropoulos V.E., Lazaris A.C., Kastriotis I. et al. Evaluation of hypoxia-inducible factor 1 a overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma//Br. J. Urol. Int. -2005. -Vol. 95. -P. 425-431.
Van Rhijn B.W., Van Der Kwast T.H., Vis A.N. et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma//Cancer Res. -2004. -Vol. 64. -P. 1911-1914.
Venyo A., Greenwood H., Maloney D. The expression оf P53 in human urothelial carcinoma//Webmed Central UROLOGY. -2010. -Vol. 1 (11). -P. 1-12.
Wolf H.K., Stober C., Hohenfellner R. et al. Prognostic value ofp53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas//Tumor Biol. -2001. -Vol. 22. -P. 328-336.
Xia G., Kumar S.R., Hawes D. et al. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer//J. Urol. -2006. -Vol. 175. -P. 1245-1252.
Yamana K., Bilim V., Hara N. et al. Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression//Br. J. Cancer. -2005. -Vol. 93. -P. 544-551.

Еще

Статья научная